Conformetrix secures first deal with two-year collaboration with AstraZeneca
This article was originally published in Scrip
Executive Summary
UK-based Conformetrix has signed its first deal by securing a two-year alliance with AstraZeneca. In addition to an undisclosed upfront payment, Conformetrix will receive research funding and be eligible for milestones as certain targets are met.